ArticleBMC cancer2012
Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey.
Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2021Pooled it
- Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Pooled it
- The perceived cancer-related financial hardship among patients and their families: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Pooled it
- Assessment of Out-of-Pocket Expenditure of HER2-Positive Breast Cancer Patients in a Tertiary Cancer Center and Private Clinics in the Philippines.Acta medica Philippina · 2026Article
- The impact of economic burden of disease on poverty among young migrant workers: evidence from China.Frontiers in public health · 2025Article
- An Overview on the Alignment of Radiation Protection in Computed Tomography withThe Malaysian journal of medical sciences : MJMS · 2023Review
- Cancer treatment-related financial toxicity in Japan: a scoping review.Frontiers in psychology · 2023Article
- Association of Health Insurance Literacy With Financial Hardship in Patients With Cancer.JAMA network open · 2022Article
- Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine.Frontiers in oncology · 2022Article
- Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature.International journal of hematology-oncology and stem cell research · 2021Review
- Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study.Contemporary clinical trials communications · 2021Article
- Developing an Educational Intervention to Address Financial Hardship in Cancer Patients.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Article
- Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.Journal of global oncology · 2019Article
- Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.Patient preference and adherence · 2018Article
- Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study.Patient preference and adherence · 2017Article
- Financial burden of colorectal cancer treatment among patients and their families in a middle-income country.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- [A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients'perspective].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.Journal of cancer research and clinical oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe financial burden of medical expenses has been increasing for cancer patients. We investigated the relationship between household income and financial burden among patients with chronic myelogenous leukaemia (CML) who have been treated with imatinib.
methodsA questionnaire was distributed to 1200 patients between May and August 2009. We retrospectively surveyed their household incomes, out-of-pocket medical expenses, final co-payments after refunds, and the perceived financial burden of their medical expenses in 2000, 2005 and 2008.
resultsA total of 577 patients completed the questionnaire. Their median age was 61 years (range, 15-94). A financial burden was felt by 41.2 % (28 of 68) of the patients treated with imatinib in 2000, 70.8 % (201 of 284) in 2005, and 75.8 % (400 of 528) in 2008. Overall, 182 patients (31.7 %) considered its discontinuation because of the financial burden and 15 (2.6 %) temporarily stopped their imatinib prescription. In 2000, 2005 and 2008, the patients' median annual household incomes were 49,615 US Dollars (USD), 38,510 USD and 36,731 USD, respectively, with an average currency exchange rate of 104 Yen/USD in 2008. Their median annual out-of-pocket expenses were 11,548, 12,067 and 11,538 USD and their median final annual co-payments were 4,375, 4,327 and 3,558 USD, respectively. Older patients (OR = 0.96, 95 % CI: 0.95-0.98, p ≪ 0.0001 for 1-year increments), and patients with higher household incomes (OR = 0.92, 95 % CI: 0.85-0.99, p = 0.03 for 10,000 USD-increments) were less likely to have considered discontinuing their imatinib treatment. Conversely, patients with higher annual final co-payments (OR = 2.21, 95 % CI: 1.28-4.28, p = 0.004 for 10,000 USD-increments) were more likely to have considered discontinuing their imatinib treatment.
conclusionsThe proportion of CML patients who sensed a financial burden increased between 2000 and 2008. During this period, their annual incomes fell by 13,000 USD, although their medical expenses did not change. Financial support for patients being treated with expensive drugs remains a major problem in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.